Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines

2000 • 1,061 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

1999 • 678 citations

Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the Lung

1987 • 484 citations

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?

2002 • 384 citations

Small Cell Lung Cancer*

2003 • 219 citations

AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK

2002 • 151 citations

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4

2003 • 141 citations

Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δ

2002 • 131 citations

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

2005 • 98 citations

Progress in the clinical development of new marine-derived anticancer compounds

2004 • 89 citations

Aplidin® induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation

2006 • 81 citations

JNK activation is critical for Aplidin™-induced apoptosis

2004 • 68 citations

Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

2006 • 68 citations

Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes

2005 • 52 citations

Treatment of small cell lung cancer

2004 • 51 citations

Second-line chemotherapy for relapsed small cell lung cancer

1997 • 47 citations

Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer

2007 • 43 citations

Recent Advances with Topotecan in the Treatment of Lung Cancer

2007 • 41 citations

Chemotherapy advances in small cell lung cancer

2006 • 27 citations

Plitidepsin Cellular Binding and Rac1/JNK Pathway Activation Depend on Membrane Cholesterol Content

2006 • 25 citations

Retreatment of Patients Surviving Cancer-Free 2 or More Years After Initial Treatment of Small Cell Lung Cancer

1996 • 24 citations

Second-line treatment of small-cell lung cancer

2006 • 19 citations

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

2005 • 13 citations

Treatment options for patients with relapsed small cell lung cancer

1993 • 7 citations

Women's experience and knowledge of adjuvant endocrine therapy (AET) for early breast cancer (BC) : a European survey

2006 • 4 citations